[go: up one dir, main page]

ZA9810490B - 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor - Google Patents

2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor

Info

Publication number
ZA9810490B
ZA9810490B ZA9810490A ZA9810490A ZA9810490B ZA 9810490 B ZA9810490 B ZA 9810490B ZA 9810490 A ZA9810490 A ZA 9810490A ZA 9810490 A ZA9810490 A ZA 9810490A ZA 9810490 B ZA9810490 B ZA 9810490B
Authority
ZA
South Africa
Prior art keywords
aryl
preparation
pharmaceutical composition
composition containing
same
Prior art date
Application number
ZA9810490A
Other languages
English (en)
Inventor
Teruya Murata
Kaoru Masumoto
Katsunori Kondo
Kiyoshi Furukawa
Makoto Oka
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Publication of ZA9810490B publication Critical patent/ZA9810490B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9810490A 1997-12-03 1998-11-17 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor ZA9810490B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP35000097 1997-12-03

Publications (1)

Publication Number Publication Date
ZA9810490B true ZA9810490B (en) 1999-05-20

Family

ID=18407561

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9810490A ZA9810490B (en) 1997-12-03 1998-11-17 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor

Country Status (27)

Country Link
US (1) US6372740B1 (xx)
EP (1) EP1036794B1 (xx)
JP (1) JP3815966B2 (xx)
KR (1) KR100494347B1 (xx)
CN (1) CN1146566C (xx)
AR (1) AR017796A1 (xx)
AT (1) ATE248169T1 (xx)
AU (1) AU744014B2 (xx)
BR (1) BR9815140A (xx)
CA (1) CA2312885C (xx)
DE (1) DE69817611T2 (xx)
DK (1) DK1036794T3 (xx)
ES (1) ES2205574T3 (xx)
HK (1) HK1028769A1 (xx)
HU (1) HUP0004422A3 (xx)
ID (1) ID24929A (xx)
IL (1) IL135920A0 (xx)
NO (1) NO20002835L (xx)
NZ (1) NZ504457A (xx)
PL (1) PL191489B1 (xx)
PT (1) PT1036794E (xx)
RU (1) RU2223272C2 (xx)
SK (1) SK285703B6 (xx)
TR (1) TR200001600T2 (xx)
TW (1) TW502034B (xx)
WO (1) WO1999028320A1 (xx)
ZA (1) ZA9810490B (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073306A1 (fr) * 1999-05-31 2000-12-07 Dainippon Pharmaceutical Co., Ltd. Derives de 2-arylpurine-9-acetamide, leur procede de preparation, compositions medicinales les contenant et intermediaires des derives

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
CN1399632A (zh) * 1999-09-27 2003-02-26 小野药品工业株式会社 嘧啶衍生物、其制备方法和含有该化合物作为有效成分的药物
RU2277096C2 (ru) 2000-07-31 2006-05-27 ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. Средства против слабоумия, содержащие производное 2-арил-8-оксодигидропурина в качестве активного ингредиента
CN1894222A (zh) * 2003-08-05 2007-01-10 沃泰克斯药物股份有限公司 作为电压门控离子通道抑制剂的稠合嘧啶化合物
JPWO2005080334A1 (ja) * 2004-02-23 2007-08-02 大日本住友製薬株式会社 新規ヘテロ環化合物
WO2005115399A2 (en) * 2004-04-16 2005-12-08 Neurogen Corporation Imidazopyrazines, imidazopyridines, ans imidazopyrimidines as crf1 receptor ligands
FR2870239B1 (fr) 2004-05-11 2006-06-16 Sanofi Synthelabo Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.
MX2007012393A (es) * 2005-04-05 2008-02-22 Pharmacopeia Inc Derivados de purina e imidazopiridina para la inmunosupresion.
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
WO2007030438A2 (en) * 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US20090281075A1 (en) * 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
WO2007104053A2 (en) * 2006-03-09 2007-09-13 Pharmacopeia, Inc. 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
WO2008043031A1 (en) * 2006-10-04 2008-04-10 Pharmacopeia, Inc. 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7915268B2 (en) * 2006-10-04 2011-03-29 Wyeth Llc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
EP2090577B1 (en) 2006-10-19 2017-04-05 Signal Pharmaceuticals, LLC Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
JP2009007273A (ja) * 2007-06-27 2009-01-15 Ajinomoto Co Inc ジアミノピリミジン化合物の製造方法
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US8473571B2 (en) 2009-01-08 2013-06-25 Microsoft Corporation Synchronizing presentation states between multiple applications
WO2011030798A1 (ja) * 2009-09-09 2011-03-17 大日本住友製薬株式会社 ８－オキソジヒドロプリン誘導体
NZ618135A (en) * 2009-10-26 2015-05-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
JP2014076947A (ja) * 2011-02-03 2014-05-01 Dainippon Sumitomo Pharma Co Ltd ２−オキシ置換８−オキソジヒドロプリン誘導体
EP2718464A1 (en) 2011-06-06 2014-04-16 Imperial Innovations Limited Methods to predict binding affinity of tspo imaging agents to tspo
CN103998036B (zh) 2011-10-19 2017-05-31 西格诺药品有限公司 利用tor激酶抑制剂治疗癌症
MX363034B (es) 2011-12-02 2019-03-06 Signal Pharm Llc Composiciones farmaceuticas de 7-(6-(2-hidroxipropan-2-il)piridin- 3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-b]pi razin-2(1h)-ona, una forma solida de las mismas y metodos de su uso.
ES2742398T3 (es) 2012-02-24 2020-02-14 Signal Pharm Llc Métodos para tratar el cáncer de pulmón no microcítico usando una terapia de combinación de inhibidores de TOR quinasa
CN102675315B (zh) * 2012-02-28 2015-04-01 中国人民解放军第四军医大学 含取代苯烷基的嘌呤类化合物和制备方法及应用
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
US9428509B2 (en) 2013-01-16 2016-08-30 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
KR20160002792A (ko) 2013-04-17 2016-01-08 시그날 파마소티칼 엘엘씨 암 치료용 tor 키나제 억제제 및 n-(3-(5-플루오로-2-(4-(2-메톡시에톡시)페닐아미노)피리미딘-4-일아미노)페닐)아크릴아미드를 포함하는 병용 요법
JP2016516815A (ja) 2013-04-17 2016-06-09 シグナル ファーマシューティカルズ，エルエルシー １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オンに関する医薬製剤、プロセス、固形形態、及び使用方法
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
NZ629332A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
NZ629411A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
EP2986321A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
CA3143529A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
JP2017511367A (ja) 2014-04-16 2017-04-20 シグナル ファーマシューティカルズ，エルエルシー １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
EP3169686A4 (en) 2014-07-14 2018-01-24 Signal Pharmaceuticals, LLC Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
EP3377493B1 (en) 2015-11-20 2020-04-08 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
CN110996955A (zh) 2017-06-22 2020-04-10 细胞基因公司 以乙型肝炎病毒感染为特征的肝细胞癌的治疗
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ． ホフマン－ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525595A1 (fr) 1982-04-27 1983-10-28 Pharmuka Lab Nouveaux derives d'arene et d'heteroarenecarboxamides et leur utilisation comme medicaments
FR2582514B1 (fr) 1985-05-30 1988-02-19 Rhone Poulenc Sante Medicaments a base d'amides, nouveaux amides et leur preparation
DK273689A (da) 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
FR2632639B1 (fr) 1988-06-09 1990-10-05 Sanofi Sa Derives d'amino-4 carboxy-3 naphtyridines, leur preparation et compositions pharmaceutiques qui les contiennent
US5856481A (en) 1994-07-28 1999-01-05 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
AU698419B2 (en) * 1996-07-03 1998-10-29 Dainippon Sumitomo Pharma Co., Ltd. A novel purine derivative
NZ335823A (en) * 1997-04-22 2001-06-29 Neurocrine Biosciences Inc Thiophenopyridines, preparation as CRF receptor antagonists
JP3814125B2 (ja) * 1999-06-02 2006-08-23 大日本住友製薬株式会社 ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073306A1 (fr) * 1999-05-31 2000-12-07 Dainippon Pharmaceutical Co., Ltd. Derives de 2-arylpurine-9-acetamide, leur procede de preparation, compositions medicinales les contenant et intermediaires des derives

Also Published As

Publication number Publication date
DE69817611D1 (de) 2003-10-02
HK1028769A1 (en) 2001-03-02
CN1284076A (zh) 2001-02-14
US6372740B1 (en) 2002-04-16
AU744014B2 (en) 2002-02-14
CA2312885C (en) 2008-01-29
NO20002835L (no) 2000-07-24
TW502034B (en) 2002-09-11
BR9815140A (pt) 2000-10-10
SK285703B6 (sk) 2007-06-07
NZ504457A (en) 2001-12-21
SK7972000A3 (en) 2001-03-12
DE69817611T2 (de) 2004-02-26
PT1036794E (pt) 2003-11-28
HUP0004422A2 (hu) 2001-04-28
TR200001600T2 (tr) 2000-11-21
ID24929A (id) 2000-08-31
ATE248169T1 (de) 2003-09-15
PL340925A1 (en) 2001-03-12
NO20002835D0 (no) 2000-06-02
AR017796A1 (es) 2001-10-24
AU1260499A (en) 1999-06-16
KR20010032686A (ko) 2001-04-25
ES2205574T3 (es) 2004-05-01
JP3815966B2 (ja) 2006-08-30
CN1146566C (zh) 2004-04-21
KR100494347B1 (ko) 2005-06-13
PL191489B1 (pl) 2006-05-31
IL135920A0 (en) 2001-05-20
EP1036794B1 (en) 2003-08-27
RU2223272C2 (ru) 2004-02-10
CA2312885A1 (en) 1999-06-10
EP1036794A4 (en) 2001-12-12
DK1036794T3 (da) 2003-12-22
HUP0004422A3 (en) 2001-10-29
WO1999028320A1 (fr) 1999-06-10
EP1036794A1 (en) 2000-09-20

Similar Documents

Publication Publication Date Title
ZA9810490B (en) 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
HUP0004024A3 (en) Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof
HU9601698D0 (en) Pharmaceutical composition
HUP0001508A3 (en) 4-arylmethylene-2-imino-2,3-dihydrothiazole derivatives, their use, process for the preparation thereof and pharmaceutical compositions containing them
IL113103A0 (en) Piperidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
IL117620A0 (en) Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
ZA962214B (en) Pharmaceutical composition
GB9519667D0 (en) Pharmaceutical composition
ZA963590B (en) Pharmaceutical composition
IL115272A0 (en) Asp-pallidipin pharmaceutical compositions containing the same and processes for the preparation thereof
ZA961051B (en) Pharmaceutical composition
ZA9610426B (en) Pharmaceutical composition
HUP0104544A3 (en) New pharmaceutical composition and the process for its preparation
IL115981A (en) Cyclolignan derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0003463A3 (en) Piperidinylmethyloxazolidinone derivative, process for its preparation pharmaceutical compositions containing it and use thereof
HU9602822D0 (en) Pharmaceutical composition
HUP9602732A3 (en) Pharmaceutical composition comprising lanperisone
ZA95736B (en) Pharmaceutical composition
HU9400523D0 (en) Pharmaceutical composition
GB9414183D0 (en) Pharmaceutical composition
GB9405024D0 (en) Pharmaceutical composition
GB9405025D0 (en) Pharmaceutical composition
GB9414182D0 (en) Pharmaceutical composition
GB9420991D0 (en) Pharmaceutical composition
GB9421239D0 (en) Pharmaceutical composition